Idatha entsha kunyango lwe-antiviral lwe-Hepatitis B kunye no-C

ISayensi yaseGileyadi namhlanje ibhengeze idatha evela kwizifundo ezininzi eziqaqambisa inzuzo yeklinikhi kunye nokwahlulwa konyango lwayo lwe-hepatitis, kunye nokuzibophelela okuqhubekayo kweGiliyadi kuphando lwesibindi ukuqhubela phambili ukupheliswa kwentsholongwane ye-hepatitis e-Asia. Idatha inikezelwa kwiNgqungquthela ye-31 ye-Asian Pacific Association for the Study of the Liver (APASL 2022), ngo-Matshi 30 - ngo-Ephreli 3, 2022 eSeoul, eMzantsi Korea.    

"Idatha yekliniki evela kwizifundo zethu yomeleza ukusebenza kakuhle kunye neeprofayili zokhuseleko lonyango lwethu kunye nenzuzo enokubakho yekliniki kubantu abaphila ne-hepatitis B kunye noC. eAsiya.” utshilo uBetty Chiang, uSekela Mongameli weMicimbi yezoNyango, iSayensi yeHlabathi, iSayensi yaseGiliyadi.

Idatha esuka kwizifundo ezintathu ezisekelwe kwi-tenofovir (TFV)-based kunyango lwe-hepatitis B (HBV) ezithiwe thaca kwinkomfa yabonisa ukuba ekuqaleni unyango izigulane ezimbalwa ezisemngciphekweni ophantsi we-hepatocellular carcinoma (HCC) ziqhubele phambili ziye kumngcipheko ophezulu, ngelixa uninzi oluphakathi okanye oluphezulu. -izigulane ezinobungozi ziphuculwe kumngcipheko ophantsi we-HCC emva konyango lwe-TFV yexesha elide.  

Idatha evela kwiSigaba se-2 sophononongo lwe-TFV disoproxil fumarate (TDF) vs. TDF/emtricitabine (FTC) kwizigulane ezinyamezelayo (IT) kunye nezifundo ezimbini zeSigaba se-3, kuthelekiswa ne-tenofovir alafenamide (TAF) vs. TDF kwi-immune-active (IA) ) izigulane zazisetyenziselwa ukuvelisa amanqaku engozi ye-HCC ngokusebenzisa i-Modified PAGE-B (mPAGE-B), isixhobo sokuqikelela ingozi ye-5 yeminyaka ye-HCC (umngcipheko ophantsi [0-≤8], umngcipheko ophakathi [9-12], kunye nomngcipheko ophezulu [≥13]). 

Kwizigulane ze-IT ze-126, i-106 (84%), i-19 (i-15%) kunye ne-1 (0.8%) yayiphantsi, ephakathi, okanye emngciphekweni omkhulu, ngokulandelanayo kwisiseko. KwiVeki ye-192, uninzi lwahlala lungatshintshwanga okanye luphuculwe. Akukho zigulana ze-IT eziphuhlise i-HCC. Kwizigulane ze-1,631 ze-IA (1,092 TAF; 539 TDF->TAF), i-901 (55%), i-588 (36%), kunye ne-142 (9%) yayiphantsi-, i-medium-, okanye i-high-risk, ngokulandelanayo kwisiseko. KwiVeki yama-240, uninzi lwahlala lungatshintshi okanye luphuculwe; kuphela izigulane ezingama-22 (2%) ezitshintshele kumngcipheko ophezulu. Ngokubanzi, iimeko ze-22 ze-HCC ziphuhlisiwe (i-0.2%, i-1.2%, kunye ne-9.2% kumaqela aphantsi, aphakathi, kunye nomngcipheko ophezulu kwisiseko).

Idatha eyongezelelweyo enikezelwe kwinkomfa ibonelela ngovavanyo lweprofayili yokhuseleko lwethambo kunye nezintso ze-TAF kuyo yonke inkqubo yophuhliso lweklinikhi ye-TAF HBV yaseGiliyadi. Idatha evela kwizigulane ze-1,911 eziphathwe nge-TAF okanye i-TDF zahlalutywa kwaye kuzo zonke iintlobo zezigulane ze-HBV ezininzi, kubandakanywa nezo zisengozini enkulu yethambo ehambelana ne-TDF kunye / okanye ubutyhefu bezintso. Iiparamitha ezizinzile okanye eziphuculweyo zamathambo kunye nezintso zabonwa ngonyango lwe-TAF xa kuthelekiswa nonyango lwe-TDF.

Kwi-hepatitis C, isifundo seSigaba se-3b esijonge kunyango-i-naïve kunye nonyango-abanamava onyango lwe-hepatitis C (CHC) engapheliyo izigulane zaseKorea lubonise ukuba unyango nge-sofosbuvir / velpatasvir kunye ne-sofosbuvir / velpatasvir / voxilaprevir luphumelele impendulo ephezulu ye-virological kunye nonyango lwe-virologic. ukusilela okanye iziganeko ezimbi kakhulu ezinxulumene nonyango. Kolunye uphononongo oluvavanya intsebenziswano enokubakho yeziyobisi (DDIs) kwizigulana zaseKorea ze-CHC zisebenzisa ii-antivirals ezisebenza ngokuthe ngqo ezifumanekayo, i-sofosbuvir/velpatasvir ibonise iprofayile ye-DDI encomekayo ngaphandle kwamazinga aphezulu okugula kunye nokuhlekisa phakathi kokuguga kwabantu be-CHC eKorea.